Headline March 15, 2018/ ''' BIG DATA BIN '''

''' BIG DATA BIN '''

ALL OVER THE WORLD  - DEVELOPED countries and developing countries, high and low, Data Center projects are a part of growing global wave investment.

Facebook is building a massive Data Center in Crook County, Ore, for the first of the two 450,000  square-foot data centers that together will cost $1 billion when completed in 2021.

The immense buildings will join the four existing data centers, totaling 1.27 million square feet, that Facebook has built here since 2010 at a cost of $1.1 billion.

They are among 11 centers the company has built in the United States and overseas.

Nearby, Apple, phew,.....PHEW..............And in your very own ecosystem, Merium, Rabo, Haleema, Dee, Zilli, Nadia,  Saima, Saira, Seher, Eman, Armeen?.......

*THE WORLD STUDENTS SOCIETY*  -will forever need to have an impregnable and absolute  policy, and a *highly encrypted and secure environment* -

To create, receive, store and manage, as a *Sacred Trust* the data of the Ecosystem 2011, Sam Daily Times, and !WOW! - the World Students Society, with all its Innovations and Evolution. 

And last year a British hospital trust was rapped by the Information Commissioners Office for  misusing data, after it passed on personal information of around 1.6  million patients to artificial-intelligence Google DeepMind.

DRUGMAKERS ARE RACING to scoop up patient health records and strike deals with technology companies as big data analytics start-

To unlock a trove of information about how medicines perform in the real world.

Studying such real world evidence offers manufacturing a powerful tool to prove the value of their drugs - something Roche aims to leverage, for example, with last month's $2 billion purchase of  Flatiron Health.

Real-world evidence involves collecting data outside traditional randomised clinical trials, the current gold standard for judging medicines, and interest in the field is ballooning.

Half of the world's 1,800 clinical studies involving real-world or real-life data since 2006 have been started in the last three years, with a record last year, according to an analysis of the US National Institutes of Health's clinicaltrials.gov website.

Hot areas for such studies include cancer, heart disease and respiratory disorders.

Historically, it has been hard to get a handle on how drugs work in routine clinical practice but the rise of electronic medical records, databases of insurance claims, fitness wearabales and even social media now offers a wealth of new data.

The ability to capture the experience of  real-world patients, who represent a wider sample of society than the relatively selection enrolled into traditional trials, is increasingly as medicines become more personalised.

However, it also opens a new front in the debate about corporate access to personal data at a time when tech giants Apple, Amazon and Google;s parent Alphabet are seeking to carve out a healthcare niche.

Some campaigners and academics worry such data will be used to primarily as a commercial tool by drugmakers and may intrude upon patients privacy.

Drugmakers Delve :

Learning from the experience of millions of patients provides granularity and is especially important in a disease like cancer which doctors want to know of there is greater benefit-

 From using a certain drug  in patients with highly specific tumour. characteristics. 

In the case of the Flatiron deal, Roche is acquiring a firm working 265 US community cancer clinics  with six major academic research centres, making it a leading curator of  oncology evidence.

Roche, which already owns 12.6 percent of  Flatiron, will pay $1.9 billion for the rest.

But interest in such such real-world data goes far beyond cancer.

All the world's major drug companies now have departments focused on the use of real-world data across multiple diseases and several have completed scientific using the information to delve into key areas addressed by their drugs.

The include Diabetes studies by AstraZeneca and Sanofi, joint research by Pfizer and Bristol Myers Squibb into stroke prevention, and a Takeda Pharmaceutical project in bowel disease.

The Honor and Serving of the  Latest  Operational Research  on Data Centers, Privacy, Records, and  Pharamaceutical giants continues. And with many thanks to researcher and author, Ben Hirschler.

With respectful dedication to the Pharma Giants, Researchers, Hospitals, Students, Professors and Teachers of the world. See Ya all on !WOW! - the World Students Society and Twitter - !E-WOW! -the Ecosystem 2011:

''' Dreams & Dreads '''

Good Night and God Bless

SAM Daily Times - the Voice of the Voiceless